Jeyasakthy Saniasiaya

Dr. Jeyasakthy Saniasiaya

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

15 September 2020 in Ear, Nose & Throat Journal
Verified
Journal Article
Open access
PDF file
JSJeyasakthy Saniasiaya
Jeyasakthy Saniasiaya
JKJeyanthi Kulasegarah
Jeyanthi Kulasegarah

5 August 2020 in Ear, Nose & Throat Journal
Verified
Journal Article
Open access
PDF file
JSJeyasakthy Saniasiaya
Jeyasakthy Saniasiaya

2 August 2022 in Journal of Asthma and Allergy
Verified
Journal Article
Open access
PDF file
Baharudin AbdullahBaharudin Abdullah
Baharudin Abdullah
ALAmir Hamzah Abdul Latiff
Amir Hamzah Abdul Latiff
AMAnura Michelle Manuel
Anura Michelle Manuel
FJFaizah Mohamed Jamli
Faizah Mohamed Jamli
HSHarvinder Singh Dalip Singh
Harvinder Singh Dalip Singh
Ralph MösgesRalph Mösges
Ralph Mösges
The goal of allergic rhinitis (AR) management is to achieve satisfactory symptom control to ensure good quality of life. Most patients with AR are currently treated with pharmacotherapy. However, knowledge gaps on the use of pharmacotherapy still exist among physicians, particularly in the primary care setting, despite the availability of guideline recommendations. Furthermore, it is common for physicians in the secondary care setting to express uncertainty regarding the use of new combination therapies like intranasal corticosteroid plus antihistamine combinations. Inadequate treatment leads to significant reduction of quality of life that affects daily activities at home, work, and school. With these concerns in mind, a practical consensus statement was developed to complement existing guidelines on the rational use of pharmacotherapy in both the primary and secondary care settings.

3 January 2017 in Oman Medical Journal
Verified
Journal Article
Open access
JSJeyasakthy Saniasiaya
Jeyasakthy Saniasiaya
RSRosdan Salim
Rosdan Salim
IMIrfan Mohamad
Irfan Mohamad
AHAzian Harun
Azian Harun
Aloe barbadensis miller or Aloe vera has been used for therapeutic purposes since ancient times with antifungal activity known to be amongst its medicinal properties. We conducted a pilot study to determine the antifungal properties of Malaysian Aloe vera leaf extract on otomycosis species including Aspergillus niger and Candida albicans. This laboratory-controlled prospective study was conducted at the Universiti Sains Malaysia. Extracts of Malaysian Aloe vera leaf was prepared in ethanol and solutions via the Soxhlet extraction method. Sabouraud dextrose agar cultured with the two fungal isolates were inoculated with the five different concentrations of each extract (50 g/mL, 25 g/mL, 12.5 g/mL, 6.25 g/mL, and 3.125 g/mL) using the well-diffusion method. Zone of inhibition was measured followed by minimum inhibitory concentration (MIC). For A. niger, a zone of inhibition for alcohol and aqueous extract was seen for all concentrations except 3.125 g/mL. There was no zone of inhibition for both alcohol and aqueous extracts of Aloe vera leaf for C. albicans. The MIC values of aqueous and alcohol extracts were 5.1 g/mL and 4.4 g/mL for A. niger and since no zone of inhibition was obtained for C. albicans the MIC was not determined. The antifungal effect of alcohol extracts of Malaysian Aloe vera leaf is better than the aqueous extract for A. niger (p < 0.001). Malaysian Aloe vera has a significant antifungal effect towards A. niger.

24 August 2021 in The Journal of Laryngology & Otology
Verified
Journal Article
Closed access
PDF file
JSJeyasakthy Saniasiaya
Jeyasakthy Saniasiaya
NPN Prepageran
N Prepageran
Objective: To outline the impact on quality of life in coronavirus disease 2019 patients with olfactory dysfunction.Methods: Five databases were searched for articles referring to the impact on quality of life in coronavirus disease 2019 patients with olfactory dysfunction. The search was conducted for the period from November 2019 to April 2021. The search was conducted over one month (May 2021).Results: Four studies that met the objective were included. Altogether, there were 1045 patients. Various questionnaires were used to assess quality of life. Overall, the quality of life deficit affected 67.7 per cent of patients. Quality of life domains investigated include overall quality of life (four studies), food and taste dysfunction (two studies), mental health (two studies), cognitive function (one study), functional outcome (one study) and safety domains (one study).Conclusion: Quality of life deficit was reported to be 67.7 per cent among coronavirus disease 2019 patients with olfactory dysfunction. The high prevalence of persistent olfactory dysfunction prompts more serious research, as the long-standing consequences of olfactory dysfunction are detrimental.